Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.

Inclusion Criteria:

• Pregnant females between 18 and 44 years of age
• Gestational age above 8 weeks
• A history of ≥3 consecutive first trimester pregnancy losses

Exclusion Criteria:

• Patients with systemic lupus erythematosus
• Positive IgG and IgM anticardiolipin antibodies
• Positive for thrombophilia screening
• Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
• Sensitive to acetylsalicylic acid, heparin, or warfarin
• Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss

Data can be shared with other researchers on a reasonable request